Citadel Advisors LLC 13D and 13G filings for Aerovate Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:58 pm Sale |
2023-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE |
Citadel Advisors LLC | 3,276 0.000% |
-1,558,705 (-99.79%) |
Filing |
| 2023-02-14 08:02 am Sale |
2022-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE |
Citadel Advisors LLC | 1,561,981 6.400% |
-35,498 (-2.22%) |
Filing |
| 2022-02-14 06:22 am Sale |
2021-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE |
Citadel Advisors LLC | 1,597,479 6.500% |
-27,695 (-1.70%) |
Filing |
| 2021-07-12 4:03 pm Purchase |
2021-07-02 | 13G | Aerovate Therapeutics, Inc. AVTE |
Citadel Advisors LLC | 1,625,174 6.700% |
1,625,174 (New Position) |
Filing |